How is the prognosis of myositis?

• Before corticosteroids era patients with myositis had a high risk of developing deep muscle weakness and consequent severe disability • premature death, mainly due to pulmonary complications, such as aspiration pneumonia or interstitial lung disease • Treatment with corticosteroids immunosuppressants and, more recently, new biologic drugs has substantially improved IIM patients survival, quality of life and disability • mortality among IIMs patients remains two- to threefold higher than the general population; most common causes of death are cancer, lung and cardiac complications, and infections. • 20 to 40 disease remission and very few recover full normal muscle function, • 60-80% of treated patients will experience a polycyclic or chronic continuous course of the disease • Poor prognostic factors in IIMs patients are • older age, • male gender, • non-Caucasian ethnicity, • longer symptom duration, • ILD, cardiac involvement, dysphagia, cancer, • specific serologic pattern (including coexistence of anti-Ro52 and anti-Jo1 antibodies, presence of anti-signal recognition particle antibody, anti-155/140, and anti-CADM-140 antibodies